Low dose naltrexone - JanOne
Alternative Names: JAN-123Latest Information Update: 28 Aug 2024
At a glance
- Originator Soin Therapeutics
- Developer JanOne
- Class Anti-inflammatories; Antineoplastics; Antivirals; Cyclopropanes; Drug withdrawal therapies; Ethers; Eye disorder therapies; Irritable bowel syndrome therapies; Ketones; Morphinans; Non-opioid analgesics; Small molecules
- Mechanism of Action Opioid receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Complex regional pain syndromes
Most Recent Events
- 28 Aug 2024 No recent reports of development identified for clinical-Phase-Unknown development in Complex-regional-pain-syndromes(In the elderly, In adults) in USA (PO, Pill)
- 29 Aug 2023 JanOne receives patent approval for low dose naltrexone in USA
- 28 Jun 2023 JanOne files for international patent protection for use of Low dose naltrexone to treat chronic pain